Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
Vivacelle Bio to Participate in BIO Partnering @ JPM Week 2025
KANSAS CITY, Mo., Jan. 9, 2025 /PRNewswire/ -- Vivacelle Bio, a late-stage biopharma company developing life-saving treatments for shock and trauma, today announced its participation in BIO Partnering @ JPM Week 2025 in San Francisco January 13-16.
堪萨斯城，密苏里州，2025年1月9日 /PRNewswire/ -- Vivacelle Bio是一家后期生物制药公司，致力于开发挽救生命的休克和创伤治疗，今天宣布将于2025年1月13日至16日在旧金山参加BIO Partnering @ JPm Week 2025。
Details of the event:
活动详情:
|
Event: |
BIO Partnering @ JPM Week 2025 |
|
Date and Time: |
January 13-16, 2025 |
|
Location: |
San Francisco Marriott Marquis & Virtual |
|
Registration: |
|
事件： |
BIO Partnering @ JPm Week 2025 |
|
日期和时间: |
2025年1月13日至16日 |
|
地点: |
旧金山万豪酒店和虚拟会议 |
|
注册： |
During the event, members of Vivacelle's management team will conduct one-on-one meetings with registered investors and potential partners, showcasing the company's business and clinical development strategy, recent corporate achievements, and anticipated milestones.
在活动期间，Vivacelle的管理团队成员将与注册投资者和潜在合作伙伴进行一对一会议，展示公司的业务和临床发展策略、近期企业成就以及预期的里程碑。
About Vivacelle Bio
Vivacelle Bio is a late-stage biopharma company developing life-saving treatments for shock and trauma. The company's lead, Phase 3 product, VBI-S, is built on its pioneering and patented phospholipid nanoparticle technology, which leverages the redistribution of nitric oxide to treat multisystem organ failure and elevate blood pressure in hypovolemic septic shock, a leading cause of death that impacts millions around the world. A Phase 2 trial of VBI-S demonstrated 100% efficacy, with the treatment resulting in elevated blood pressure in hypovolemic septic shock patients who are refractory to therapy and markedly improved organ dysfunction. In addition to venture capital, Vivacelle has garnered backing and financial support from the US Department of Defense and the National Institutes of Health. Vivacelle Bio is headquartered in Kansas City, MO. Learn more at .
关于Vivacelle Bio
Vivacelle Bio是一家晚期生物制药公司，正在开发救命的休克和创伤治疗方案。公司的主要产品VBI-S处于第三阶段，基于其开创性和专利的磷脂纳米颗粒技术，利用一氧化氮的重新分配来治疗多系统脏器衰竭，并在低血容量败血性休克中提高血压，这是一种导致数百万生命损失的主要死亡原因。VBI-S的第二阶段试验显示出100%的疗效，在治疗对常规治疗无反应的低血容量败血性休克患者时，血压显著提高，脏器功能障碍明显改善。除了创投资金外，Vivacelle还得到了美国国防部和国立卫生研究院的支持和资金支持。Vivacelle Bio总部设在密苏里州堪萨斯城。了解更多信息请访问。
The company's Phase 3 study is funded by the Naval Medical Research Command (NMRC) – Naval Advanced Medical Development (NAMD) program via the Medical Technology Enterprise Consortium (MTEC).
公司的第三阶段研究由海军医学研究指挥部（NMRC）资助，资助来源于海军先进医疗开发（NAMD）项目，通过医疗技术企业联盟（MTEC）进行。
About MTEC
The Medical Technology Enterprise Consortium (MTEC) is a 501(c)(3) biomedical technology consortium collaborating under an Other Transaction Agreement (OTA) with the U.S. Army Medical Research and Development Command (USAMRDC) that serves those who serve our nation. For more information about MTEC, visit mtec-sc.org.
关于MTEC
医疗技术企业联盟（MTEC）是一个501(c)(3)的生物医药技术联盟，依据与美国陆军医学研究与开发指挥部（USAMRDC）签订的其他交易协议（OTA）进行合作，致力于服务于为国家服务的人士。有关MTEC的更多信息，请访问mtec-sc.org。
The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.
本文件中所包含的观点和结论仅代表作者个人意见，不应被视为美国政府的正式政策或支持，无论是明示还是暗示。
Contact
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
[email protected]
联系
投资者关系
提伯伦战略顾问公司
大卫·爱尔兰
(231) 632-0002
[email protected]
Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
[email protected]
媒体关系
提伯伦战略顾问公司
凯西·麦克唐纳
(646) 577-8520
[email protected]
SOURCE Vivacelle Bio
来源 Vivacelle Bio
